Cargando…
Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
Combination antiretroviral therapy (cART) is effective but not curative, and no successful vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly neutralizing antibodies (bNAbs) provide a new approach to HIV-1 prevention and treatment, and these promising candidates advan...
Autores principales: | Liu, Yubin, Cao, Wei, Sun, Ming, Li, Taisheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040474/ https://www.ncbi.nlm.nih.gov/pubmed/31985356 http://dx.doi.org/10.1080/22221751.2020.1713707 |
Ejemplares similares
-
Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
por: Landais, Elise, et al.
Publicado: (2018) -
Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies
por: Zhang, Zhiqing, et al.
Publicado: (2016) -
The expanding array of HIV broadly neutralizing antibodies
por: McCoy, Laura E.
Publicado: (2018) -
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
por: Dufloo, Jérémy, et al.
Publicado: (2018) -
Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)